Bluejay Diagnostics shares surge 24.75% intraday after announcing $4.5M private placement for FDA approval and R&D.

Bluejay Diagnostics (NASDAQ:BJDX) surged 24.75% intraday following announcements of a $4.5 million private placement and an expanded partnership with SanyoSeiko to advance its Symphony platform commercialization. The private placement, priced at-the-market under Nasdaq rules, provided capital for FDA approval efforts and R&D, signaling operational progress. Concurrently, the expanded collaboration with SanyoSeiko reinforced investor confidence in the company’s diagnostic technology commercialization strategy. Both events, disclosed on October 9-10, 2025, directly addressed key growth catalysts, aligning with the intraday rally. Earlier updates, such as a $3.7 million warrant deal in April 2025, lacked the immediate impact of these recent developments.